Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324878 | 0.86 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL13359381 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL17901790 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL13324875 | 0.82 | L3MBTL1 (0.42) | ALDH1A1SMN1; SMN2HPGDGAAL3MBTL1 | |
| SCHEMBL14557548 | 0.78 | HPGD (0.36) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL20311441 | 0.78 | CYP3A4 (0.58) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL738198 | 0.77 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL20413346 | 0.77 | CHRM1 (0.42) | ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL18292237 | 0.77 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 | |
| SCHEMBL13912231 | 0.75 | SMN1; SMN2 (0.58) | ALDH1A1SMN1; SMN2HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714131-B2 | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070072858-A1 | Process for the stereoselective preparation of (-)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072858-A1 | Process for the stereoselective preparation of (-)-halofenate and derivatives thereof | METABOLEX, INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072858-A1 | Process for the stereoselective preparation of (-)-halofenate and derivatives thereof | CCNY, C1S, CBR3 | ALDH1A1 3229/4885SMN1; SMN2 4772/4885HPGD 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.